- Trials with a EudraCT protocol (212)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
212 result(s) found for: Drug allergy.
Displaying page 1 of 11.
EudraCT Number: 2009-017828-54 | Sponsor Protocol Number: 1131/09 | Start Date*: 2011-03-28 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to -lactams. | |||||||||||||
Medical condition: allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003856-22 | Sponsor Protocol Number: C-07-01 | Start Date*: 2017-11-07 | |||||||||||
Sponsor Name:Alcon Research Ltd | |||||||||||||
Full Title: Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray in 6-11 Year old Patients. | |||||||||||||
Medical condition: Seasonal Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001318-14 | Sponsor Protocol Number: PHT-01-13 | Start Date*: 2013-07-15 | |||||||||||
Sponsor Name:PH&T SpA | |||||||||||||
Full Title: MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED, CLINICAL STUDY TO DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF SEASO... | |||||||||||||
Medical condition: SEASONAL ALLERGIC RHINITIS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000754-19 | Sponsor Protocol Number: AL1602av | Start Date*: 2017-11-09 | |||||||||||||||||||||||||||||||
Sponsor Name:Allergopharma GmbH & Co. KG | |||||||||||||||||||||||||||||||||
Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) PL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002409-13 | Sponsor Protocol Number: AL1501AV | Start Date*: 2015-11-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Allergopharma GmbH & Co. KG | |||||||||||||||||||||||||||||||||
Full Title: A multicenter, randomized, open-label clinical trial to evaluate safety and tolerability of a year-round initiation of specific immunotherapy with an aluminum hydroxide adsorbed allergoid preparati... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001538-18 | Sponsor Protocol Number: 603-PG-PSC-74 | Start Date*: 2004-09-23 | |||||||||||
Sponsor Name:LETI Pharma GmbH | |||||||||||||
Full Title: A randomised, double blinded, placebo controlled multicentre study for the efficacy and safety of Depigoid birch pollen | |||||||||||||
Medical condition: Patients have to suffer from IgE mediated allergic rhinits, rhinoconjunctivitis +/- asthma due to sensitization again birch pollen. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005400-28 | Sponsor Protocol Number: AL1502AV | Start Date*: 2016-06-20 | |||||||||||||||||||||||||||||||
Sponsor Name:Allergopharma GmbH & Co. KG | |||||||||||||||||||||||||||||||||
Full Title: Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhin... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma during the birch pollen season | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013269-24 | Sponsor Protocol Number: 1268.41 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: Randomised, double-blind, triple dummy, partial cross-over (each active treatment with placebo) study using an Environmental Challenge Chamber (ECC) to assess the safety and efficacy of 2 weeks of ... | |||||||||||||
Medical condition: Allergic rhinitis due to pollen | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002296-42 | Sponsor Protocol Number: SC-21A | Start Date*: 2020-01-31 | ||||||||||||||||||||||||||
Sponsor Name:ROXALL Medizin GmbH | ||||||||||||||||||||||||||||
Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy | ||||||||||||||||||||||||||||
Medical condition: Allergic rhinitis / rhino-conjunctivitis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002319-27 | Sponsor Protocol Number: SL-61A | Start Date*: 2021-02-01 | ||||||||||||||||||||||||||
Sponsor Name:ROXALL Medizin GmbH | ||||||||||||||||||||||||||||
Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from birch pollen allergy | ||||||||||||||||||||||||||||
Medical condition: Birch pollen-related allergic rhinitis / rhino-conjunctivitis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000097-38 | Sponsor Protocol Number: LLB-2016-01 | Start Date*: 2016-02-17 |
Sponsor Name:Labo'Life | ||
Full Title: Randomized, double-blind, placebo-controlled study to measure 2L®ALERG (homeopathic drug) efficacy on symptoms of allergic rhinitis and allergic rhinoconjunctivitis in patients with a seasonal alle... | ||
Medical condition: Patients: Allergic Rhinitis and allergic rhinoconjunctivitis in patients with seasonal allergy to grass pollen | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004094-52 | Sponsor Protocol Number: R5713-5714-5715-ALG-2001 | Start Date*: 2021-02-19 |
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||
Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis | ||
Medical condition: Birch Pollen Allergy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002881-42 | Sponsor Protocol Number: SL-351A | Start Date*: 2023-02-07 | ||||||||||||||||||||||||||
Sponsor Name:ROXALL Medizin GmbH | ||||||||||||||||||||||||||||
Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergy | ||||||||||||||||||||||||||||
Medical condition: Patients with grass pollen-related allergic rhinitis/rhino-conjunctivitis (with well-controlled mild-to-moderate or without asthma) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004185-14 | Sponsor Protocol Number: CDPG103ADE01 | Start Date*: 2012-02-29 | |||||||||||||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldeh... | |||||||||||||||||||||||
Medical condition: Allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000442-35 | Sponsor Protocol Number: CS-BM32-003 | Start Date*: 2012-05-10 | |||||||||||
Sponsor Name:Biomay AG | |||||||||||||
Full Title: PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY | |||||||||||||
Medical condition: Grass pollen allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SI (Completed) AT (Completed) BE (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000548-25 | Sponsor Protocol Number: AL1605av | Start Date*: 2018-06-18 | |||||||||||||||||||||||||||||||
Sponsor Name:Allergopharma GmbH & Co. KG | |||||||||||||||||||||||||||||||||
Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) PL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004050-31 | Sponsor Protocol Number: SAN-0677 | Start Date*: 2022-04-04 | |||||||||||
Sponsor Name:Lek Pharmaceuticals d.d. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo and active controlled parallel-group trial to assess the efficacy and safety of the fixed combination medicinal product Mometasone furoate + Azelast... | |||||||||||||
Medical condition: Seasonal allergic rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005939-15 | Sponsor Protocol Number: DC04/RUP/3/08 | Start Date*: 2009-02-11 | ||||||||||||||||
Sponsor Name:J. Uriach y Compañía, S.A. | ||||||||||||||||||
Full Title: Efficacy and safety of rupatadine in persistent allergic rhinitis and health-related quality of life in children age 6-11 years: A randomized, double blind, placebo-controlled clinical trial. | ||||||||||||||||||
Medical condition: Persistent Allergic Rhinitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002259-32 | Sponsor Protocol Number: AN004T | Start Date*: 2012-08-14 | |||||||||||
Sponsor Name:Anergis SA | |||||||||||||
Full Title: A multicentre, double-blind, placebo-controlled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT, a combination of contiguous overlapping peptides derived ... | |||||||||||||
Medical condition: Desensitization by Specific ImmunoTherapy (SIT) in subjects allergic to birch pollen | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) LT (Completed) DK (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001227-12 | Sponsor Protocol Number: M19-850 | Start Date*: 2020-03-13 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3b, open label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study | |||||||||||||
Medical condition: Moderate to severe Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FI (Completed) HU (Completed) CZ (Completed) ES (Ongoing) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) HR (Completed) IT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
